Examples of using Dacogen in English and their translations into Hungarian
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Financial
-
Programming
-
Official/political
-
Computer
Do not use Dacogen.
What Dacogen contains.
How to store Dacogen.
Dacogen is an anti-cancer medicine.
Medication name Dacogen.
Dacogen contains potassium and sodium.
Other medicines and Dacogen.
Why has Dacogen been approved?
If you forget your appointment to have Dacogen.
What Dacogen looks like and contents of the pack.
Myelosuppression caused by Dacogen is reversible.
Dacogen 50 mg powder for concentrate for solution for infusion.
You may feel tired or weak after using Dacogen.
You will be given Dacogen when you are first diagnosed with AML.
Your doctor, nurse or pharmacist is responsible for storing Dacogen.
What benefit has Dacogen shown during the studies?
Dacogen is a powder that is made up into a solution for infusion(drip) into a vein.
Talk to your doctor, pharmacist or nurse before using Dacogen if you have.
Dacogen is not for use in children or adolescents under the age of 18.
If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Dacogen.
This is because Dacogen can affect the way some other medicines work.
Dacogen is an anti-cancer medicine. It contains the active substance‘decitabine'.
You should not use Dacogen if you are pregnant as it may harm your baby.
Dacogen is a white to almost white powder for concentrate for solution for infusion.
You will be given Dacogen when you are first diagnosed with AML. It is used in adults.
Dacogen is contraindicated during breast-feeding; therefore if treatment with this medicine is required, breast-feeding must be discontinued(see section 4.3).
Patients receiving Dacogen lived for an average of 7.7 months compared with 5.0 months for patients receiving supportive care or treatment with cytarabine.
If Dacogen is used during pregnancy, or if a patient becomes pregnant while receiving this medicinal product, the patient should be apprised of the potential hazard to the foetus.
In the Dacogen treatment group, there was a higher incidence of treatment discontinuation due to adverse events in women compared to men(43% versus 32%).